JP2019503361A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019503361A5 JP2019503361A5 JP2018532781A JP2018532781A JP2019503361A5 JP 2019503361 A5 JP2019503361 A5 JP 2019503361A5 JP 2018532781 A JP2018532781 A JP 2018532781A JP 2018532781 A JP2018532781 A JP 2018532781A JP 2019503361 A5 JP2019503361 A5 JP 2019503361A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitors
- inhibitor
- vegf
- antigen
- growth factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 108090001123 antibodies Proteins 0.000 description 4
- 102000004965 antibodies Human genes 0.000 description 4
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 239000000611 antibody drug conjugate Substances 0.000 description 3
- 108091008116 antibody drug conjugates Proteins 0.000 description 3
- 102100011842 CEACAM5 Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100010782 EGFR Human genes 0.000 description 2
- 101700039191 EGFR Proteins 0.000 description 2
- 102100003017 MAGEA3 Human genes 0.000 description 2
- 101710027664 MAGEA3 Proteins 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 210000001744 T-Lymphocytes Anatomy 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000003042 antagnostic Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000038129 antigens Human genes 0.000 description 2
- 108091007172 antigens Proteins 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 102000006639 indoleamine 2,3-dioxygenase family Human genes 0.000 description 2
- 108020004201 indoleamine 2,3-dioxygenase family Proteins 0.000 description 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 102100007747 ANGPT2 Human genes 0.000 description 1
- 101710043855 ANGPT2 Proteins 0.000 description 1
- 101700025229 Ang2 Proteins 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 102100009333 BTLA Human genes 0.000 description 1
- 101700047069 BTLA Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108010005144 Bevacizumab Proteins 0.000 description 1
- 102100005826 CD19 Human genes 0.000 description 1
- 101700087100 CD19 Proteins 0.000 description 1
- 102100013078 CD47 Human genes 0.000 description 1
- 101700033237 CD47 Proteins 0.000 description 1
- 229920002574 CR-39 Polymers 0.000 description 1
- 102100006400 CSF2 Human genes 0.000 description 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 1
- 229940121652 CTLA-4 inhibitors Drugs 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 1
- 108010022830 Cetuximab Proteins 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 229950003468 Dupilumab Drugs 0.000 description 1
- 229960001433 Erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100016384 HAVCR2 Human genes 0.000 description 1
- 101710004393 HAVCR2 Proteins 0.000 description 1
- -1 ICOS Proteins 0.000 description 1
- 102100005026 IL21 Human genes 0.000 description 1
- 102100014193 IL7 Human genes 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010089187 Ipilimumab Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 102100017213 LAG3 Human genes 0.000 description 1
- 108060004270 LAG3 Proteins 0.000 description 1
- 102100016650 LAIR1 Human genes 0.000 description 1
- 101700010670 LAIR1 Proteins 0.000 description 1
- 102100008857 MLANA Human genes 0.000 description 1
- 101710012533 MLANA Proteins 0.000 description 1
- 102100006037 MUC1 Human genes 0.000 description 1
- 229960001156 Mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000012271 PD-L1 inhibitor Substances 0.000 description 1
- 229940121656 PD-L1 inhibitors Drugs 0.000 description 1
- 102100006771 PKM Human genes 0.000 description 1
- 101710039160 PKM Proteins 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- 108010062724 Ranibizumab Proteins 0.000 description 1
- 229960003876 Ranibizumab Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 102100006047 TIGIT Human genes 0.000 description 1
- 101700052319 TIGIT Proteins 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 102000003298 Tumor Necrosis Factor Receptors Human genes 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 108091007928 VEGF receptors Proteins 0.000 description 1
- 102100015314 VSIR Human genes 0.000 description 1
- 101710036075 VSIR Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000000139 costimulatory Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 108091003598 dupilumab Proteins 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037240 fusion proteins Human genes 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229930003347 taxol Natural products 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- 229960005486 vaccines Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
Description
特定の実施形態において、本発明の方法は、放射線、外科手術、がんワクチン、ＰＤ−Ｌ１阻害剤（例えば、抗ＰＤ−Ｌ１抗体）、ＬＡＧ３阻害剤、ＣＴＬＡ−４阻害剤（例えば、イピリムマブ）、ＴＩＭ３阻害剤、ＢＴＬＡ阻害剤、ＴＩＧＩＴ阻害剤、ＣＤ４７阻害剤、別のＴ細胞共阻害剤（ｃｏ−ｉｎｈｉｂｉｔｏｒ）またはリガンドのアンタゴニスト（例えば、ＣＤ−２８、２Ｂ４、ＬＹ１０８、ＬＡＩＲ１、ＩＣＯＳ、ＣＤ１６０またはＶＩＳＴＡに対する抗体）、インドールアミン−２，３−ジオキシゲナーゼ（ＩＤＯ）阻害剤、血管内皮増殖因子（ＶＥＧＦ）アンタゴニスト［例えば、アフリベルセプトもしくは米国特許第７，０８７，４１１号に記載されている他のＶＥＧＦ阻害融合タンパク質のような「ＶＥＧＦ−トラップ」または抗ＶＥＧＦ抗体もしくはその抗原結合断片（例えば、ベバシズマブまたはラニビズマブ）またはＶＥＧＦ受容体の低分子キナーゼ阻害剤（例えば、スニチニブ、ソラフェニブまたはパゾパニブ）］、Ａｎｇ２阻害剤（例えば、ネスバクマブ）、形質転換増殖因子ベータ（ＴＧＦβ）阻害剤、上皮増殖因子受容体（ＥＧＦＲ）阻害剤（例えば、エルロチニブ、セツキシマブ）、共刺激受容体に対するアゴニスト（例えば、グルココルチコイド誘導性ＴＮＦＲ関連タンパク質に対するアゴニスト）、腫瘍特異的抗原に対する抗体（例えば、ＣＡ９、ＣＡ１２５、黒色腫関連抗原３（ＭＡＧＥ３）、がん胎児性抗原（ＣＥＡ）、ビメンチン、腫瘍−Ｍ２−ＰＫ、前立腺特異的抗原（ＰＳＡ）、ムチン−１、ＭＡＲＴ−１およびＣＡ１９−９）、ワクチン（例えば、バチルスカルメット・ゲラン、がんワクチン）、抗原提示を増加させるためのアジュバント（例えば、顆粒球マクロファージコロニー刺激因子）、細胞毒素、化学療法剤（例えば、ダカルバジン、テモゾロミド、シクロホスファミド、ドセタキセル、ドキソルビシン、ダウノルビシン、シスプラチン、カルボプラチン、ゲムシタビン、メトトレキサート、ミトキサントロン、オキサリプラチン、パクリタキセルおよびビンクリスチン）、放射線療法、ＩＬ−６Ｒ阻害剤（例えば、サリルマブ）、ＩＬ−４Ｒ阻害剤（例えば、デュピルマブ）、ＩＬ−１０阻害剤、ＩＬ−２、ＩＬ−７、ＩＬ−２１およびＩＬ−１５のようなサイトカイン、抗体−薬物コンジュゲート（ＡＤＣ）（例えば、抗ＣＤ１９−ＤＭ４ ＡＤＣおよび抗ＤＳ６−ＤＭ４ ＡＤＣ）、キメラ抗原受容体Ｔ細胞（例えば、ＣＤ１９標的化Ｔ細胞）、抗炎症薬（例えば、コルチコステロイドおよび非ステロイド系抗炎症薬）、ならびに抗酸化物質のような栄養補助食品からなる群から選択される第３の治療剤の投与または治療を含む。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562270749P | 2015-12-22 | 2015-12-22 | |
| US62/270,749 | 2015-12-22 | ||
| PCT/US2016/068030 WO2017112775A1 (en) | 2015-12-22 | 2016-12-21 | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019503361A JP2019503361A (ja) | 2019-02-07 |
| JP2019503361A5 true JP2019503361A5 (ja) | 2020-01-23 |
| JP7126941B2 JP7126941B2 (ja) | 2022-08-29 |
Family
ID=57799835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532781A Active JP7126941B2 (ja) | 2015-12-22 | 2016-12-21 | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20170174779A1 (ja) |
| EP (1) | EP3394103B1 (ja) |
| JP (1) | JP7126941B2 (ja) |
| KR (1) | KR20180089444A (ja) |
| CN (1) | CN108473578A (ja) |
| AU (1) | AU2016378721B2 (ja) |
| BR (1) | BR112018012801B1 (ja) |
| CA (1) | CA3009161A1 (ja) |
| DK (1) | DK3394103T3 (ja) |
| EA (1) | EA201891428A1 (ja) |
| ES (1) | ES2954153T3 (ja) |
| FI (1) | FI3394103T3 (ja) |
| HK (1) | HK1255040A1 (ja) |
| HR (1) | HRP20231156T1 (ja) |
| HU (1) | HUE063377T2 (ja) |
| IL (1) | IL259924A (ja) |
| LT (1) | LT3394103T (ja) |
| MA (1) | MA44146B1 (ja) |
| MD (1) | MD3394103T2 (ja) |
| MX (1) | MX2018007613A (ja) |
| PL (1) | PL3394103T3 (ja) |
| PT (1) | PT3394103T (ja) |
| RS (1) | RS64588B1 (ja) |
| SG (2) | SG11201804765UA (ja) |
| SI (1) | SI3394103T1 (ja) |
| WO (1) | WO2017112775A1 (ja) |
| ZA (1) | ZA201804681B (ja) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| CN110981964B (zh) | 2013-01-14 | 2023-09-15 | Xencor股份有限公司 | 新型异二聚体蛋白 |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| AU2014232416B2 (en) | 2013-03-15 | 2017-09-28 | Xencor, Inc. | Modulation of T Cells with Bispecific Antibodies and FC Fusions |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| KR102497443B1 (ko) | 2014-03-28 | 2023-02-08 | 젠코어 인코포레이티드 | Cd38 및 cd3에 결합하는 이중특이적 항체 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| PE20171103A1 (es) | 2014-11-26 | 2017-08-07 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y cd38 |
| CA2967426A1 (en) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and tumor antigens |
| US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
| US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| CN108699136B (zh) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | 结合cd3和psma的异二聚抗体 |
| TWI755395B (zh) | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
| RU2022104399A (ru) | 2016-06-14 | 2022-05-05 | Ксенкор, Инк. | Биспецифические антитела-ингибиторы контрольных точек |
| AU2017290086A1 (en) | 2016-06-28 | 2019-01-24 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| SG11201900201YA (en) | 2016-08-16 | 2019-02-27 | Regeneron Pharma | Methods for quantitating individual antibodies from a mixture |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| CN110214148A (zh) | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | 含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白 |
| SG11201902667UA (en) | 2016-10-25 | 2019-05-30 | Regeneron Pharma | Methods and systems for chromatography data analysis |
| BR112019010878A2 (pt) * | 2016-11-29 | 2019-10-01 | Lindhofer Horst | combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| WO2018220446A1 (en) | 2017-06-01 | 2018-12-06 | Compugen Ltd. | Triple combination antibody therapies |
| WO2018223004A1 (en) * | 2017-06-01 | 2018-12-06 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 |
| MX2019014274A (es) * | 2017-06-02 | 2020-01-23 | Hoffmann La Roche | Metodo de tratamiento. |
| MA49517A (fr) | 2017-06-30 | 2020-05-06 | Xencor Inc | Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène |
| EP3661954B1 (en) * | 2017-08-03 | 2022-02-09 | Amgen Inc. | Interleukin-21 muteins and methods of treatment |
| ES2928576T3 (es) | 2017-09-08 | 2022-11-21 | Amgen Inc | Inhibidores de KRAS G12C y métodos de uso de los mismos |
| CA3075927A1 (en) * | 2017-09-20 | 2019-03-28 | Regeneron Pharmaceuticals, Inc. | Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden |
| JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体 |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| JP2021506291A (ja) | 2017-12-19 | 2021-02-22 | ゼンコア インコーポレイテッド | 改変されたｉｌ−２ ｆｃ融合タンパク質 |
| CR20210319A (es) | 2018-01-12 | 2021-07-27 | Amgen Inc | ANTICUERPOS ANTI-PD-1 Y MÉTODOS DE TRATAMIENTO (Div. 2020-330) |
| WO2019152743A1 (en) * | 2018-01-31 | 2019-08-08 | Celgene Corporation | Combination therapy using adoptive cell therapy and checkpoint inhibitor |
| CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
| CN112437777A (zh) | 2018-04-18 | 2021-03-02 | Xencor股份有限公司 | 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白 |
| EP3781599A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| TW202005985A (zh) * | 2018-06-21 | 2020-02-01 | 美商再生元醫藥公司 | 用雙特異性抗ＣＤ３ｘＭＵＣ１６抗體及抗ＰＤ－１抗體治療癌症的方法 |
| TW202005694A (zh) | 2018-07-02 | 2020-02-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| TWI822815B (zh) * | 2018-07-14 | 2023-11-21 | 財團法人生物技術開發中心 | 抗-人類ｐｄ-ｌ１之抗體及其用途 |
| US11358999B2 (en) | 2018-10-03 | 2022-06-14 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
| WO2020092499A1 (en) | 2018-10-31 | 2020-05-07 | Regeneron Pharmaceuticals, Inc. | Method and system of identifying and quantifying a protein |
| US11249089B2 (en) | 2018-12-12 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | System and method of analysis of a protein using liquid chromatography-mass spectrometry |
| WO2020176699A1 (en) | 2019-02-28 | 2020-09-03 | Regeneron Pharmaceuticals, Inc. | Administration of pd-1 inhibitors for treating skin cancer |
| CA3132185A1 (en) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
| JP6881658B2 (ja) | 2019-07-05 | 2021-06-02 | 小野薬品工業株式会社 | Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療 |
| CN114206924A (zh) | 2019-12-06 | 2022-03-18 | 瑞泽恩制药公司 | 抗vegf蛋白组合物及其制备方法 |
| US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
| KR102607909B1 (ko) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
| EP4222171A1 (en) * | 2020-10-02 | 2023-08-09 | Regeneron Pharmaceuticals, Inc. | Combination of antibodies for treating cancer with reduced cytokine release syndrome |
| EP3988568A1 (en) | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Combination treatment |
| KR20230157315A (ko) | 2021-01-28 | 2023-11-16 | 리제너론 파마슈티칼스 인코포레이티드 | 사이토카인 방출 증후군을 치료하기 위한 조성물 및 방법 |
| US20240076373A1 (en) | 2021-01-28 | 2024-03-07 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies |
| EP4284516A1 (en) | 2021-01-28 | 2023-12-06 | Compugen Ltd. | Anti-pvrig antibodies formulations and uses thereof |
| CA3212665A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
| CN114133449A (zh) * | 2021-12-14 | 2022-03-04 | 厦门大学附属第一医院 | 一种检测淋巴细胞表面pd-1受体的抗体组合物及其应用 |
| WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
| WO2023201226A1 (en) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| EP3222634A1 (en) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| AU2012288413B2 (en) | 2011-07-24 | 2016-10-13 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| PL3192812T3 (pl) * | 2013-12-17 | 2020-10-19 | Genentech, Inc. | Przeciwciała anty-CD3 i sposoby ich zastosowania |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI754319B (zh) * | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
-
2016
- 2016-12-21 PT PT168265577T patent/PT3394103T/pt unknown
- 2016-12-21 LT LTEPPCT/US2016/068030T patent/LT3394103T/lt unknown
- 2016-12-21 JP JP2018532781A patent/JP7126941B2/ja active Active
- 2016-12-21 FI FIEP16826557.7T patent/FI3394103T3/fi active
- 2016-12-21 ES ES16826557T patent/ES2954153T3/es active Active
- 2016-12-21 SG SG11201804765UA patent/SG11201804765UA/en unknown
- 2016-12-21 HR HRP20231156TT patent/HRP20231156T1/hr unknown
- 2016-12-21 KR KR1020187017751A patent/KR20180089444A/ko active Search and Examination
- 2016-12-21 SI SI201631733T patent/SI3394103T1/sl unknown
- 2016-12-21 DK DK16826557.7T patent/DK3394103T3/da active
- 2016-12-21 MX MX2018007613A patent/MX2018007613A/es unknown
- 2016-12-21 MA MA44146A patent/MA44146B1/fr unknown
- 2016-12-21 RS RS20230829A patent/RS64588B1/sr unknown
- 2016-12-21 WO PCT/US2016/068030 patent/WO2017112775A1/en active Application Filing
- 2016-12-21 EP EP16826557.7A patent/EP3394103B1/en active Active
- 2016-12-21 AU AU2016378721A patent/AU2016378721B2/en active Active
- 2016-12-21 SG SG10202005670TA patent/SG10202005670TA/en unknown
- 2016-12-21 CN CN201680075172.2A patent/CN108473578A/zh active Pending
- 2016-12-21 CA CA3009161A patent/CA3009161A1/en active Pending
- 2016-12-21 EA EA201891428A patent/EA201891428A1/ru unknown
- 2016-12-21 HU HUE16826557A patent/HUE063377T2/hu unknown
- 2016-12-21 PL PL16826557.7T patent/PL3394103T3/pl unknown
- 2016-12-21 BR BR112018012801-5A patent/BR112018012801B1/pt active IP Right Grant
- 2016-12-21 MD MDE20181060T patent/MD3394103T2/ro unknown
- 2016-12-21 US US15/386,453 patent/US20170174779A1/en not_active Abandoned
-
2018
- 2018-06-10 IL IL259924A patent/IL259924A/en unknown
- 2018-07-13 ZA ZA2018/04681A patent/ZA201804681B/en unknown
- 2018-11-06 HK HK18114163.2A patent/HK1255040A1/zh unknown
-
2021
- 2021-03-24 US US17/210,860 patent/US20210214457A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019503361A5 (ja) | ||
| Ruffo et al. | Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor | |
| Franke et al. | Immunotherapy for colorectal cancer: a review of current and novel therapeutic approaches | |
| Marin-Acevedo et al. | Cancer immunotherapy beyond immune checkpoint inhibitors | |
| AU2017302668B2 (en) | Combination therapies of chimeric antigen receptors and PD-1 inhibitors | |
| US20200339651A1 (en) | Methods for b cell preconditioning in car therapy | |
| Huehls et al. | Bispecific T‐cell engagers for cancer immunotherapy | |
| CN106687483B (zh) | 使用人源化抗-bcma嵌合抗原受体治疗癌症 | |
| EP3423482A1 (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
| Litterman et al. | Profound impairment of adaptive immune responses by alkylating chemotherapy | |
| EP3574005A1 (en) | Cd28 compositions and methods for chimeric antigen receptor therapy | |
| Goel et al. | Cancer immunotherapy in clinical practice—the past, present, and future | |
| JP2018538339A (ja) | 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体（ｃａｒ）およびｐｄ−ｌ１阻害剤に対する抗体 | |
| Spellman et al. | Immunotherapy for breast cancer: past, present, and future | |
| Sun et al. | Immunotherapy in human colorectal cancer: challenges and prospective | |
| JP2017522879A (ja) | Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置 | |
| KR20160119867A (ko) | 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료 | |
| Ingles Garces et al. | Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer | |
| Shiozawa et al. | Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells | |
| JP2019070056A5 (ja) | ||
| WO2016172537A1 (en) | Compositions to disrupt protein kinase a anchoring and uses thereof | |
| JP2017014254A5 (ja) | ||
| MX2021011750A (es) | Anticuerpos anti-egfrviii y fragmentos de union a antigenos de los mismos. | |
| van Rooijen et al. | Immunotherapeutic options on the horizon in breast cancer treatment | |
| Wang et al. | What happens to the immune microenvironment after PD-1 inhibitor therapy? |